Nota Bene Episode 36: My Two Cents: Executive and Legislative Branch Check-In, FDA’s Regulations, EU Competition Law Reform, and Using Blockchain Technology
In this recap episode host Michael Cohen extracts the valuable lessons shared by our guests in the prior 5 episodes. He offers his two cents about the practical advice shared by our guests to help the C-Suite understand the legal, political, and economic underpinnings impacting the 21st intercontinental business landscape in which they operate.
Subscribe on Apple Podcasts, Google Play or Stitcher to receive every new episode as soon as they're published!
In Episode 31 and Episode 33, we checked in on the Executive and Congressional branches of the government with Jonathan Meyer and Elizabeth Frazee, respectively. Both guests shared their insights on happenings such as the Mexican border closure, the approaching potential fiscal cliff, Mueller report myths, the Paris Climate Agreement, the state of Puerto Rico, and privacy regulations. What do all of these events mean for the C-Suite?
In Episode 32, we explored a snapshot of the Food and Drug Administration (FDA) with Allison Fulton, where she shared the past and future state of the agency. We also discussed its comparison to similar agencies in other countries. Michael's conversation with Allison created a sense of belief that it’s possible for the government to be an ally to businesses.
In Episode 34, we looked at pending European Union reforms and what they might mean for the multi-national order with Robert Klotz. Robert shared his insight on proposed European Union competition law reforms and their impact on EU companies.
In Episode 35, we replayed a former episode covering blockchain technology with James Gatto. Jim explained what blockchain is and how companies can use this technology in areas involving smart contracts and supply-chain management. Even though blockchain is a term many are now familiar with, it’s still uncertain how well people understand this technology and how it works.